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Summary
Sequential multiple assignment randomization trial (SMART) is a powerful design to study 
Dynamic Treatment Regimes (DTRs) and allows causal comparisons of DTRs. To handle practical 
challenges of SMART, we propose a SMART with Enrichment (SMARTer) design, which 
performs stage-wise enrichment for SMART. SMARTer can improve design efficiency, shorten the 
recruitment period, and partially reduce trial duration to make SMART more practical with limited 
time and resource. Specifically, at each subsequent stage of a SMART, we enrich the study sample 
with new patients who have received previous stages’ treatments in a naturalistic fashion without 
randomization, and only randomize them among the current stage treatment options. One extreme 
case of the SMARTer is to synthesize separate independent single-stage randomized trials with 
patients who have received previous stage treatments. We show data from SMARTer allows for 
unbiased estimation of DTRs as SMART does under certain assumptions. Furthermore, we show 
analytically that the efficiency gain of the new design over SMART can be significant especially 
when the dropout rate is high. Lastly, extensive simulation studies are performed to demonstrate 
performance of SMARTer design, and sample size estimation in a scenario informed by real data 
from a SMART study is presented.
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1. Introduction
Dynamic Treatment Regimes (DTRs), also referred to as adaptive treatment regimes or 
tailored treatment regimens, are sequential treatment rules tailored at each stage by patients’ 
time-varying characteristics and intermediate treatment responses (Thall et al., 2000; Lavori 
et al., 2000; Murphy et al., 2007; Dawson and Lavori, 2004). For example, an oncologist 
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patient’s tumor response to induction therapy to guide the use of second-line therapy. 
Sequential multiple assignment randomization trials (SMARTs) (Lavori and Dawson, 2000, 
2004; Murphy, 2005) generalize conventional randomized clinical trials to make causal 
comparisons of such DTRs. In SMARTs, patients are randomized to different treatments at 
each critical decision stage, where randomization probabilities may depend on patients’ 
time-varying response (e.g., changes in symptom severity, drug-resistance, treatment 
adherence) up to that stage. These trials also provide rich information to infer optimal 
treatment regimens tailored to individual patients. Murphy (2005) provides inferences and 
sample size formula to compare two DTRs in SMARTs, Almirall et al. (2012) proposed to 
use SMART design as a pilot study for building effective DTRs, and Nahum-Shani et al. 
(2012) illustrated several important design issues and primary analyses for SMART studies. 
Cheung et al. (2015) introduced an adaptive randomization scheme for a sequential multiple 
assignment randomized trial of DTRs. Lastly, Shortreed et al. (2014) discussed handling 
missing data for SMART through multiple imputation with applications to the CATIE study 
(Stroup et al., 2003).
We use a real study (Kasari et al., 2014) to illustrate DTR and concepts in SMART. Kasari et 
al. (2014) conducted a SMART on communication intervention for minimally verbal 
children with autism. The study is a two-stage SMART targeted on testing the effect of a 
speech-generating device (SGD). We present the original diagram of the study in Figure 1. 
In the first stage, 61 children were randomized to a blended developmental/behavioral 
intervention (JASP + EMT) with or without augmentation of a SGD for 12 weeks with equal 
probability. At the end of the 12th week, children were assessed for early response versus 
slow response to stage 1 treatment. In the second stage, the early-responders continued with 
the first stage treatments. The slow-responders to (JASP + EMT) were randomized to (JASP 
+ EMT + SGD) or intensified (JASP + EMT + SGD) with equal probability. The slow 
responders to JASP+EMT+SGD were not re-randomized. The second stage lasted 12 weeks 
and followed by a follow-up stage of 12 weeks. In this article, the primary aim was to 
compare the first stage treatment options SGD (JASP + EMT + SGD) versus spoken words 
alone (JASP + EMT). Secondary aim was to compare the dynamic treatment regimes 
(DTRs), namely: 1) beginning with JASP + EMT + SGD and intensifying JASP + EMT + 
SGD for slow responders; 2) beginning with JASP + EMT and to increase the intensity for 
slow responders; 3) beginning with JASP + EMT and to switch JASP + EMT + SGD for 
slow responders.
The cost of multistage and multitreatment studies such as SMARTs is high and the length of 
trial period is long (March et al., 2010). The implementation for administering multiple 
stages of multiple treatment is likely to be complex and operational cost can be high. 
Furthermore, study dropout is a common phenomenon in randomized clinical trials (RCTs) 
regardless of investigator’s best efforts to keep patients in the study. For example, meta 
analyses of study dropout rate for RCTs of antipsychotic drugs treating schizophrenia 
reported an average attrition rate of greater than 30% (Martin et al., 2006; Kemmler et al., 
2005). In the Clinical Antipsychotic Trials of Intervention and Effectiveness (CATIE) study 
(Schneider et al., 2003), the attrition was 48% with 705 of 1460 patients staying for the 
entire 18 months. In some other SMARTs, the dropout rate was lower but still persists as in 
regular RCTs. In ExTENd for example (Lei et al., 2012), there was a drop-out rate of 17% 
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during the first-stage treatment (52 out of 302), and an additional 13% during the second 
stage (41 out of 302).
In this article, we propose a stage-wise enrichment design to improve efficiency of SMART 
estimations. The key component is to include an enrichment sample who have received first 
stage treatments in a naturalistic fashion but will undergo randomization for the second stage 
treatments. This new design can be considered as a meta-analytic approach to enrich 
SMART sample and to synthesize single-stage trials without sacrificing the central feature of 
SMART to make causal conclusions. We show that the proposed SMART with Enrichment 
design (SMARTer) and its appropriate analysis method will boost the efficiency of SMART, 
improve practicability of SMART, address the attrition issue from the design and analysis 
perspective, and avoid pitfalls of incorrect inference on long-term DTR effect when 
combining single-stage randomized trials. Specifically, the proposed methodology can 
potentially 1) synthesize single-stage trials to integrate information to make causal inference 
on DTRs as is possible in a multi-stage SMART, while substantially shortening the trial time 
frame; 2) extract information from patients dropping out from the first stage; 3) recruit and 
randomize additional patients to the second-stage treatments without requiring 
randomization of the first-stage treatments, and thus achieve the same or superior efficiency 
as if there were no dropouts, which reduces the sample size of the initial stage and the 
overall sample size.
It is of interest to note that SMARTer design differs from an intuitive approach that pieces 
together results from separate randomized trials conducted at separate stages, as criticized in 
previous literature (Murphy et al., 2007; Collins et al., 2014). For the latter, an investigator 
may determine the best first-line treatment based on a conventional randomized trial 
comparing several first-line treatments and then next, compare second-line treatments for a 
new group of subjects already treated by the “best” first-stage treatment. Essentially, this 
intuitive approach compares available intervention options at each stage separately to infer 
the best DTR. It has several disadvantages (Murphy et al., 2007): first, it does not capture the 
delayed effect when the long-term effect begins to appear in latter stages; second, it fails to 
take into account the prescriptive effect of an early stage treatment which may not yield a 
larger intermediate outcome; third, single-stage trials tend to enroll more homogeneous 
patients to increase power for detection of treatment differences whereas SMART would not. 
In terms of design, SMARTer does not recommend enriching the sample with only the 
subjects who have received the “best” first-line treatment inferred from a single-stage trial. 
Instead, we recruit enrichment samples from subjects who have received any of the first-line 
treatments so that the enrichment population includes patients with all possible combinations 
of both lines of treatments to properly account for delayed effect and prescriptive effect. The 
main focus of SMARTer design is to improve efficiency through enrichment samples who 
only receive randomization in the latter stages. In terms of the analysis, instead of inferring 
the best treatment from each single stage separately, SMARTer can be used to infer optimal 
DTRs with backward induction algorithms such as Q-learning (Murphy and Collins, 2007), 
which uses the randomized samples for each stage including the enrichment participants.
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2.1. Rationales of SMARTer Design
The essential idea of a SMARTer design is to consider stage-wise enrichment: at the kth 
stage (k > 1), augment the original SMART with new patients randomized among the kth 
stage treatment options without requiring randomization of previous stage treatments. Figure 
2 illustrated the enrichment for a two-stage SMART with no intermediate outcomes. 
Generalizations to more than two stages and including intermediate outcomes are similar. 
Assume that n patients are randomized at the first stage in a SMART. Some patients 
complete the first stage treatment and undergo the second stage randomization (group 1), 
while some patients drop out before the second stage randomization (group 2). To improve 
efficiency and mitigate the problem of attrition after the first stage treatment, while the 
original SMART is progressing, we concurrently recruit m new patients as the enrichment 
sample (group 3). One key eligibility criterion for the enrichment group is that they have 
received one of the first stage treatments without randomization prior to the enrollment. For 
the enrichment subjects in group 3, their second-stage treatments will be randomized as in 
the original SMART.
Taking the autism study (Kasari et al., 2014) as an example, the primary outcome for this 
study was the total number of spontaneous communicative utterances (TSCU). The response 
status to the first stage treatment was the intermediate outcome that the second stage 
treatment choice and randomization probability depended on. For example, for a DTR 
starting with JASP + EMT, whether a patient participates in the second randomization to add 
SGD or intensify depends on whether he/she is a slow responder or not. Group 1 patients 
would be those who were randomized in the first stage and stayed through the trial until the 
end of the second stage. Group 2 patients include the six patients who dropped out after 
randomization in the first stage, and the additional three patients who dropped out after 
finishing first stage and on whom the intermediate response variables were recorded. In the 
next few sections, we will provide analysis of efficiency and sample size computation for the 
enrichment group three patients in the new SMARTer design to estimate the mean outcome 
of a given DTR and compare DTRs.
The final analysis sample of SMARTer consists of three groups of patients (also shown in 
Figure 2). Specifically, group 1 is the n1 SMART subjects who stay through two stages of 
randomization and treatments; group 2 is the n2 SMART subjects who drop out before the 
second randomization; and group 3 is the m enrichment subjects who only receive the 
second-stage randomization with known first-stage treatment history. Let Zi denote the 
indicator of stage 2 completion status for subject i, Si denote pre-treatment information at 
stage 1, Aki denote treatment at stage k (k = 1, 2), and Yi denote the observed outcome from 
the study. Then SMARTer data consists of the data from the original SMART subjects, (Si, 
A1i, ZiA2i, ZiYi, i = 1, …, n), and the data from the m enrichment subjects, (Sj, A1j, A2j, Yj, 
j = 1, …, m). In the subsequent presentation, we assume Si to take a finite number of discrete 
values for convenience.
To understand why SMARTer enables valid evaluation of DTRs under certain assumptions, 
we first focus on a two-stage trial and assume that there is no intermediate information after 
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stage 1. For any DTR (d1, d2), a sequence of decision rules with dk representing a function 
mapping historical information to the domain of Ak for k = 1, 2, our goal is to estimate the 
value function of (d1, d2) defined as E[Y (d1, d2)]. Here, Y (a1, a2) is the potential outcome 
associated with the treatment assignment (a1, a2). We assume the following conditions hold:
(C.1) Y = Σa1,a2 Y (a1, a2)I (A1 = a1, A2 = a2); (C.2) sequential ignorability or non-
informative dropout: the dropout is independent of {Y (a1, a2)} given (S, A1); (C.3) no 
selection bias: the conditional mean of Y given (S, A1) in the enrichment group is the same 
as that in the original SMART population; (C.4) the first stage domain of A1 (treatment 
options) for the enrichment group is identical to the treatment A1 in the SMART population.
Condition (C.1) is the standard stable unit treatment value assumption (SUTVA) in causal 
inference. Condition (C.2) is the sequential ignorability, non-informative dropout, or missing 
at random (MAR) assumption also required in any analysis of an RCT. The key condition 
(C.3) requires no selection bias in the sense that the conditional treatment effect given S is 
the same between the original SMART samples and the enrichment samples. This 
assumption is required to use the enrichment sample to estimate E(Y (a1, a2)|S, A1 = a1, A2 
= a2) and ensure the DTR estimands are the same in the enrichment population and the 
original SMART population. (C.4) ensures the first stage treatments are comparable in the 
SMART and enrichment samples. We further discuss these assumptions in Section 6.
Under conditions (C.1)–(C.4), we show SMARTer can provide an unbiased estimation of the 
average potential outcome under the DTR (d1, d2), that is, E[Y (d1, d2)]. Due to sequential 
ignorability, potential outcomes {Y (a1, a2)} are conditionally independent of A2 given (S, 
A1) in the enrichment sample, even if their first stage treatments is received in a naturalistic 
fashion without randomization. When comparing first stage treatment options, we only use 
the non-dropouts from the original SMART and estimate outcomes for n2 dropouts whose 
first stage treatments are randomized. Thus potential outcomes {Y (a1, a2)} for these 
subjects are also independent of A1. Let pk (ak |sk ) denote the randomization probability of 
Ak given a patient’s covariates collected up to stage k, that is, sk. Note that for simplicity, 
here we assume the second stage randomization probabilities depend on baseline covariates 
and first stage treatments. In Section 2.3, we generalize to allow them to depend on 
intermediate outcomes. Our key result is to show
Eg[·] denotes the expectation for subjects in group g, and Y* denotes the conditional mean of 
Y given (S, A1, A2 = d2(S, A1)) for subjects in group 1 and 3. The rationale is that if this 
equality holds, then the average causal outcome, E[Y (d1, d2)], can be estimated unbiasedly 
using the data from SMARTer since Y*, E1[·], and E2[·] can be estimated unbiasedly using 
their corresponding empirical averages. There are three observations of this result: 1) since 
group 1 subjects’ final outcomes Y are observed, we estimate their average causal mean 
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using their observed outcomes; 2) group 2 subjects drop out after first-stage and have 
missing Y, but their outcomes can be estimated as Y* from subjects in group 1 and 3; 3) 
group 3 subjects contribute to the estimation through estimating missing outcomes for 
subjects in group 2.
To see why the above equalities hold, first note that under condition (C.1), we obtain
By randomization, A2 is independent of potential outcome Y (d1, d2) given (S, A1). Thus, 
since E1[·] is equivalent to E[·] under the non-informative dropout condition (C.2), the above 
expression becomes
Furthermore, by randomization of A1 in the first stage for group 1 subjects, we obtain the 
above equation to also equal the average causal outcome, that is,
Next, due to randomization of A2 for subjects in group 1 and group 3, under condition (C.3), 
we obtain
Consequently,
Again, by the randomization of A1 for subjects in group 2, we conclude μ2 = E[Y (d1, d2)].
2.2. Value Estimation and Inference in SMARTer
Given a DTR (d1, d2), for a patient with S = s and treatment assignment a1 = d1(s) and a2 = 
d2(s, a1), an estimator of the expected outcome value associated with this DTR is
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where Ŷ(s, a1, a2) is the predicted outcomes for group 2 subjects using group 1 and group 3 
data:
The essential idea is to estimate the group 2 outcomes from the outcomes of group 1 and 3. 
The enrichment sample improves estimation efficiency by adding more samples for the 
nonparametric estimation. Note that from (1), even without an enrichment sample (i.e., m = 
0), we can still estimate group 2 subjects’ outcomes using group 1 subjects’ to improve 
efficiency with no bias. It is clear that the estimator in (1) adheres to the intention-to-treat 
principal (Fisher et al., 1989) such that all subjects randomized are analyzed according to 
their original treatment assignments.
Next, we derive the asymptotic variance formula for estimator (1) under the conditions (C.1) 
through (C.4) assuming m = O(n). Specifically, we wish to obtain the asymptotic expansion 
of μ̂(d1, d2) − μ(d1, d2). To this end, we let p(s) be the probability of S = s and p(a1|s) be the 
randomization probability of A1 = a1 given S = s in the SMART population in the first stage 
and let p(a2|s, a1) be the randomization probability of A2 = a2 given S = s and A1 = a1 in the 
second stage. These two conditional probabilities are known by design. Furthermore, we let 
q(s) and q(a1|s) be the probability of enrichment sample with S = s and receiving first-stage 
treatment A = a1 given S = s. Note that we allow the baseline covariates to have different 
distribution in the enrichment sample (q(s)) and SMART sample (p(s)), and the observed 
conditional probability q(a1|s) can be different from the randomization probability p(a1|s). 
We denote π1(s, a1, a2) = p(a2|s, a1)p(a1|s)p(s), π2(s, a1, a2) = p(a1|s)p(s)I (d2(s, a1) = a2), 
and π3(s, a1, a2) = p(a2|s, a1)q(a1|s)q(s). Finally, denote α(s, a1) = P (Z = 1|S = s, A1 = a1), β 
= m/n, and r(s, a1) = q(a1|s)q(s)/[p(a1|s)p(s)].
We show in Web Appendix A the asymptotic variance of μ̂(d1, d2) is V/n, where
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The first term is the variability from subjects in group 1 and imputing outcomes for group 2, 
and the second term is the variability from enrichment subjects in group 3. The variance can 
be estimated by its empirical form.
Finally, to compare two DTRs, we can use the difference of SMARTer estimators for two 
DTRs (d1, d2) and ( ), that is, . Then its asymptotic variance is 
, where
This variance can also be estimated by its empirical form.
2.3. Incorporating Intermediate Outcomes
The previous section assumes no intermediate outcome is available especially for subjects 
who drop out from the SMART. When intermediate outcomes are available, the treatment 
rule d2 may depend on the intermediate outcome. In this case, the observed data from a 
SMARTer consist of (S1i, A1i, S2i, ZiA2i, ZiYi), i = 1, …, n, for i in the original SMART 
group, and the enrichment group observations (S1j, A1j, S2j, A2j, Yj), j = 1, …, m. Here, we 
use S1 to denote pre-treatment covariates at stage 1 and S2 to denote intermediate outcomes 
and other covariates collected prior to stage 2. For simplicity of derivation, we assume S1i 
and S2j to be discrete. Similar to (1), a consistent estimator of the associated value using 
both the SMART and enrichment observations is
where Ŷ(s1, a1, s2, a2) is the imputed outcome from the second-stage data given as
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The asymptotic variance is similar to before by re-defining πk (s, a1, a2) as πk (s1, a1, s2, a2) 
through conditioning on both the baseline covariates S1 and intermediate outcome S2. That 
is,
3. Design Efficiency of SMARTer
In this section, we study the efficiency gain or loss of the proposed design as compared to a 
SMART with no dropout. For simplicity of illustration, we assume P(Z = 1|A1, S) to be a 
constant α and let ω(s) = r(d1(s), s). Furthermore, we denote p(d1(s)|s) = p1(s) and p(d2(s, 
d1(s))|d1(s), s) = p2(s), so the variance of μ̂(d1, d2) is V/n with
where Es[·] is the expectation with respect to S in the SMART population,
When α = 1, that is, no participant drops out from SMART, V reduces to
which is the variance formula given in Murphy (2005) for SMART. Therefore, to measure 
the efficiency gain of the proposed design over SMART design without dropouts, we define 
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relative efficiency ρ = V0/V, where ρ > 1 implies the proposed enrichment design is more 
efficient than the original SMART without dropout.
To further gain insights on efficiency comparison, we consider a special situation when 
treatment randomization does not depend on tailoring variables, that is, p1(S) = p1, p2(S) = 
p2. We assume that the enrichment population is close to the SMART population so ω(s) ≈ 
1, and let the ratio of within- and between-strata variance to be γ ≈ Eσ(s)2/E(ν(s) − μ(d1, 
d2))2. Let α denote the completion (non drop-out) rate, and β = m/n denote the enrichment 
rate. We can show (2) holds and details are included in Web Appendix B.
(2)
From (2), the relative efficiency depends on randomization probabilities, within- and 
between-strata (S) variability and distribution ratios between the enrichment and SMART 
populations. Note that ρ > 1 implies the proposed SMARTer is more efficient than a 
SMART without enrichment and no dropout. From the expression of ρ, we thus conclude:
i. When α = 1, there is no dropout after the first stage in SMARTer, our estimator 
reduces to be the same as the estimator in Murphy (2005), and thus ρ = 1.
ii. When α = 0, that is, all subjects drop out after the first stage, ρ ≈ (1 + γ)/(p2 + γ/
β). There is efficiency gain if β >γ /(1 + γ − p2). More specifically, there is 
always efficiency gain if β > 1. Note that this is the extreme case in the sense 
that all subjects drop out and we synthesize two independent randomized trials 
on the two stages.
iii. For any 0 < α < 1, if α(1 + β)2 + β(1 − α)2 ≤ (α + β)2, ρ > 1 implies efficiency 
gain. Particularly, the latter condition holds if we choose β ≥ 1.
Figure 3 is the contour plot of ρ as a function of completion rate α and the enrichment rate β 
= m/n under γ = 0.5, 2, where each line represents the contour line of the marked relative 
efficiency ρ as defined above. For example, for the ρ = 0.9 line, α = 0.6 corresponds to β = 
0.5. That is, at 60% completion rate, a study needs to enrich 50% sample to obtain a 
SMARTer estimator with variance 1/0.9 ≈ 1.11 times the variance of SMART estimator with 
the same initial sample size but no dropout. Similarly, at the same completion rate, to 
achieve the same efficiency, β needs to be above 0.75; and to achieve a relative efficiency of 
ρ = 1.1, β needs to be above 1.05. Note that the line with equal efficiency has a slow change 
rate indicating the increase of enrichment sample size is not sensitive to completion rate. 
The contour lines above the equal efficiency line (ρ = 1) are convex and increasing, 
indicating with lower dropout rate after the first stage, SMARTer requires more enrichment 
patients at the second stage to achieve higher efficiency than a SMART with no dropout. The 
opposite can be seen from the contour lines below the equal efficiency line which are 
concave and decreasing: with lower dropout rate, SMARTer requires less enrichment 
patients or no enrichment to achieve efficiency slightly lower than a SMART with no 
dropout.
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Another way to understand the design efficiency of SMARTer is through sample size 
calculation for comparing two DTRs in a SMARTer study. We denote the difference in the 
mean outcome value as Δμ and assume the type I error rate of a two-sided test is 0.05 and 
80% power to detect a difference. In the above simplified setting, the total sample size of 
SMARTer is , where σ2(d̄2) = var(Y |Ā2 = d̄2), and zq represents the q-
th upper quantile of a standard normal distribution. With a completion rate of α, the sample 
size of SMART inflates to  to ensure sufficient power at the end of the 
second stage. For two DTRs with different first stage treatments, that is,  for 
any S, one can compute the variance of the difference as . 
Assuming , then ρ is also the ratio of variance of SMART and SMARTer 
estimator for comparing two DTRs. Thus the sample size of initial recruitment (n) for a 
SMARTer is  to achieve the same efficiency. Table 1 provides the 
sample sizes for a SMARTer with an initial sample of n subjects and an enrichment sample 
of m subjects to achieve the same efficiency as a SMART recruiting 100 subjects and in an 
ideal case of no dropout. For example, if 40% patients drop out after the first stage 
randomization of SMARTer and the within- and between-stratum variance ratio γ = 1, Table 
1 provides three combinations of initial stage and enrichment sample sizes for SMARTer to 
achieve the same efficiency: (109, 54), (80, 80), and (62, 124). In contrast, when accounting 
for dropouts at the design stage for a SMART without enrichment, one needs 100/0.6=250 
subjects.
4. Simulation Studies
Simulations results are based on 1000 replications of samples with initial enrollment of n = 
800 patients. They demonstrate the consistency and comparative efficiency of SMARTer 
compared with SMART under various scenarios with or without intermediate outcomes.
4.1. Simulation Results without Intermediate Outcomes
Here, we assume there are two stages each with 2 candidate treatments, A1 and A2, and a 
randomization probability of 1/2. The baseline covariate S1 takes random integer values (0, 
1, 2) with probabilities (1/3, 1/3, 1/3). Let S2 = A1(1 − S1), and the final outcome after the 
second stage is Y = S2 + A2(1 − S1) + I (S1 = 1, A1 = 1, A2 = −1) + e, where e ~ (0, 1). 
The optimal dynamic rules for this setting are d1(S1) = 2I (S1 < 2) − 1 and d2(S1, A1) = 2I 
(S1 < 1) − 1. Under this rule ν(S1 = 0) = 2, ν(S1 = 1) = 1, ν(S1 = 2) = 2, thus the optimal 
rule has a value of μ(d1, d2) = 1.667. We consider two levels of completion rates α = 0, 0.5, 
three levels of enrichment proportions β = 0.5, 1, 2 and two scenarios for the m enrichment 
patients: scenario 1 simulates the distribution of A1 for the enrichment patients the same as 
initially recruited patients, that is, q(A1|S1) = p(A1|S1) = 1/2, the baseline covariate has the 
same distribution in the enrichment sample and the SMART sample; and scenario 2 
simulates different observed A1 distribution q(A1 = 1|S1) = 1/(1 + exp(−0.5(2I(S1 < 2) 
− 1))), that is, the enrichment patients are more likely to receive the optimal first-stage 
treatment, and the baseline covariate S1 takes random integer values (0, 1, 2) with 
probabilities (1/2, 1/4, 1/4) for the enrichment sample.
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Table 2 presents SMARTer estimators of a single DTR and comparison of two DTRs, as 
well as their efficiency gain (ρ) compared with SMART without dropout. We provide the 
estimates for the optimal treatment regime d1(S1) = 2I(S1 < 2) − 1 and d2(S1, A1) = 2I (S1 < 
1) − 1, and its comparison with an one-size-fits-all regime,  and 
, for which the mean outcome is μ′ = 0
The results show the accuracy of the variance estimation and the simplified formula (2) of 
comparative efficiency. When all patients drop out (α = 0), the relative efficiency ρ increases 
from about 0.5 to 2 when the enrichment size m increases from 0.5 to 2 times the original 
sample size n; when half of patients drop out (α = 0.5), the relative efficiency ρ increases 
from about 0.9 to 1.3. As β increases, SMARTer is more efficient compared to SMART 
design even when all patients drop out after the initial randomization (α = 0) and SMARTer 
combines two single-stage randomized trials. We also observe that the relative efficiency ρ 
for comparing two DTRs is greater (more efficient) than estimating a single DTR.
4.2. Simulation Results with Intermediate Outcomes
The general settings are the same with Section 5.1. The intermediate outcome before the 
second stage treatment S2 is simulated from a logistic model, where logit{P(S2 = 1|S1, A1)} 
= A1(1 − S1), and the outcome after the second stage treatment is Y = S2 + A2(1 − X) + I (X 
= 1)A2(2S2 − 1) + e, where e ~ (0, 1). The dynamic rules we are considering is the 
optimal rule under this scenario, which also depends on the intermediate outcome S2: d1(S1, 
A1) = 2I (S1 = 1) − 1 and d2(S1) = I (S1 ≠ 1)(2I(S1 = 0) − 1) + I (S1 = 1)sign(2S2 − 1). Under 
this rule , ν(S1 = 1) = 1.5, . Thus the mean outcome for 
the optimal rule is μ(d1, d2) = 1.654 with equal baseline distribution for S1.
Table 3 presents SMARTer estimators of both a single DTR and comparison of two DTRs, 
as well as their efficiency gain (ρ) compared with SMART estimator with no dropout. We 
present the estimates for the optimal DTR and its comparison with an one-size-fits-all rule: 
 and , for which the mean outcome is μ′ = 0.5. The true 
mean difference is 1.154. The results are similar to the case without intermediate outcome. 
When β = 1, ρ̂ is approximately equal or larger than 1, and it is higher for the difference 
comparison in Table 3. We observe that SMARTer estimator has efficiency gain even with β 
= 1 and it may boost efficiency especially when comparing two DTRs.
5. Sample Size Calculation for an Autism SMART Study
We illustrate the sample size calculation and potential efficiency gain using results from the 
autism study (Kasari et al., 2014) introduced in Section 2.1. For the primary aim, the study 
found that SGD(JASP + EMT + SGD) has a better treatment effect compared with spoken 
words alone (JASP + EMT). Secondary aim results suggest that the adaptive intervention 
beginning with JASP + EMT + SGD and intensifying JASP + EMT + SGD for children who 
were slow responders led to better post-treatment outcomes.
Suppose we stratify by baseline variables and responding status (early or slow) after the first 
stage. Here, we provide the sample size calculation for comparing two adaptive treatment 
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regimes as in the secondary study aim: one is starting with JASP + EMT + SGD and 
intensifying JASP + EMT + SGD for children who are slow responders (d̄2); the other is 
starting with JASP + EMT, and the slow-responders to JASP + EMT receive 
.
The original planned sample size was based on the primary aim to compare TSCU for two 
treatments in stage 1. The study assumed an attrition rate of 10% by week 24, and the 
planned total sample size was n = 97 to detect a moderate effect size of 0.6 in TSCU with 
80% power using a two-sided two-sample t-test with a type I error rate of 5%. The actual 
study recruited 61 patients. The effect size for the primary aim comparison was 0.62 and it 
was significant at 0.05 level despite the insufficient power. As a secondary aim of the study, 
the effect size of the embedded DTRs d̄2 and  for TSCU at week 24 was 0.55. There were 
approximately 15% patients dropped out after the first stage at week 12. The comparison of 
two DTRs in the secondary aim had approximately a power of 37% to detect a moderate 
effect size of 0.5.
We examine whether one can design a SMARTer to enrich the trial in the second stage so 
that the power for comparing two DTRs can be improved. To this end, note that , 
where Δμ is the effect size, and . When γ = 0.5, we 
have Zβ ≤ −0.115 and we can achieve at most 55% in power by enrichment in the second 
stage. To achieve 80% power, at least 151 patients need to be recruited in the first stage.
Table 4 provides sample sizes for SMARTer and SMART that achieve the same power of 90, 
85, or 80% for two-sided tests with a type I error rate of 5%. The sample size for the initial 
stage of SMARTer is computed by , where we take into account 
d̄2 was randomized only in the first stage and for , only the 40% slow responders received 
two-stages of randomization. The enrichment ratio β is computed by solving 
 (by independence of subjects following d̄2 and ), that is, to 
solve the following equation 
. The solution is .
Since we do not have information on the ratio of within and between stratum variances γ, 
we provide results for three ratios γ = 0.2, 0.5, 1 and also two rates of attrition 15 and 40% 
after the first stage. According to Table 4, for this specific example, SMARTer would have 
smaller total sample size for initial recruitment and enrichment when γ is small (γ = 0.2) 
with attrition rate 15% and for γ = 0.5 with attrition rate 40%. SMARTer requires a smaller 
total number of patients than SMART if the within stratum variance is small, where one can 
estimate Ŷi for dropouts using enrichment sample with more accuracy due to using a more 
homogeneous enrichment group. When the dropout rate is high, recruiting an enrichment 
sample to recover the missing information is more beneficial and SMARTer demonstrates 
greater advantages in terms of a smaller total sample size.
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We propose a SMARTer design to improve efficiency of SMART by stage-wise enrichment 
in a multi-stage trial. We have shown that the new design retains the validity of making 
causal inference for DTRs and the efficiency gain is significant if the enrichment sample size 
is substantial and drop out rate is considerable. In all numerical results, we compared 
efficiency of SMARTer to SMART with no dropout. When comparing with SMART 
accounting for dropouts, the efficiency gain is expected to be greater than that shown here. 
One interesting application of SMARTer design is the extreme case when α = 0, the 
proposed design is equivalent to synthesizing different independent trials from each stage. 
One important implication is that if the conditions (C.1)–(C.4) hold, that is, the treatment 
response profiles given covariates are the same for the participants from each stage, and the 
treatment history in previous stages can be obtained from the enrichment sample, then it 
may be possible to not conduct a full SMART study but to synthesize existing trials 
conducted at separate stages to evaluate and compare DTRs, at least for the purpose of 
discovering optimal DTRs. At the other extreme, when there is no attrition (i.e., α = 1) 
SMARTer can still be used to gain efficiency by replacing Yi in μ̂ (d1, d2) by the 
corresponding stratum mean estimated from the combined SMART and enrichment sample, 
which is less variable.
Although enrichment can improve the power for comparing DTRs, the maximal power that 
can be achieved still depends on the sample size in the first stage recruitment. Recruiting an 
enrichment sample can decrease the within-stratum variation of estimated DTRs but cannot 
decrease the between-stratum variation. Therefore, in a SMART with high dropout rate in 
the first stage of treatment, SMARTer may act as a salvage design to mitigate high drop out 
rate and improve power. In addition, one reason for the low participation rate in clinical 
trials and high attrition is the need for frequent in-person visits and the resulting time and 
travel costs (Ross et al., 1999), which can be reduced for the enrichment samples in 
SMARTer since these participants have already received first stage treatments. For the 
enrichment sample, the cost of monitoring first stage treatment is saved, and the duration of 
trial for this group can be less than recruiting patients to undergo multiple randomizations.
Here, the enrichment sample is only used to estimate outcomes for those who drop out from 
the original SMART randomized for the first stage treatments, and thus the enrichment 
samples are not directly included in the comparisons of the first-stage treatments. The 
second stage treatments are randomized in the enrichment samples and health information 
collected right before second stage randomization (including intermediate outcomes) is 
matched with the SMART group. Thus under the assumption (C.2) and (C.3) of the same 
conditional distribution given health information up to stage 2, valid inference can be drawn 
by estimating outcomes using enrichment sample for dropouts from the SMART. When no 
unmeasured confounding assumption is likely to hold, one can consider including 
enrichment sample for the first-stage treatment comparisons through propensity score 
adjustment. Data collected from the SMARTer can also be used to find optimal DTR (details 
in Web Appendix E). When two DTRs of interest start with the same first stage treatment, 
there are shared data used in the estimation of DTRs. Our method can be extended to allow 
for shared path between DTRs being compared by properly handling correlation between 
Liu et al. Page 14













observations on the shared path using the asymptotic linear expansion of the variance given 
in the Web appendix A. More discussion of this issue is given in Kidwell and Wahed 
(Kidwell and Wahed). In practice, when continuous pre-treatment covariates S may be 
encountered, the proposed method can be directly applied by discretizing S. An alternative is 
to estimate Ŷ(s, a1, a2) by regression model. The former may lead to a less tailored DTR, 
that is, DTR only depends on discretized S; while the latter leads to a more tailored DTR but 
can be biased if the model is misspecified.
When the dropout patterns are complicated and depend on many intermediate outcomes, our 
simple estimation by stratification and matching may need to be improved. A 
straightforward modification is to match by cumulative summaries of main variables (e.g., 
number of interim outcome measures). Other model based methods or doubly robust 
estimation may be considered for more complex situations especially when auxiliary 
variables are available for estimating missingness. When exact measures of treatment history 
or health history are not available in the enrichment sample, one may consider collecting 
proxies such as summary statistics or cumulative information of treatment history (e.g., 
treatment history within past few months) to replace exact measures. In the recent literature 
(March et al., 2010), extended follow-up is implemented using survey methodology or 
through extracting clinical data from electronic health records. New research methods may 
be considered in designing a SMARTer. From a design point of view, although we allow the 
distribution of first-stage treatment history and covariates on the enrichment participants to 
be different from the SMART population, the more similar they are, the more efficiency we 
will gain by using the enrichment participants. This implies that when recruiting enrichment 
patients for the second stage treatments, similar inclusion/exclusion criteria as SMART may 
be used and appropriate sampling design may be implemented to improve matching.
Four assumptions are required for a valid inference using SMARTer. Assumptions (C.1) is 
required for regular RCTs and SMARTs to ensure causal interpretation. In practice, 
assumptions (C.2) and (C.3) might be violated when there is informative dropout or 
selection bias between SMART and enrichment sample, that is, when the conditional mean 
response is different due to different distribution of some unmeasured baseline covariates 
associated with the outcome. Sensitivity analyses in Web Appendix C and D show that 
results are robust to small or moderate deviation from the assumptions.
One complication regarding assumption (C.4) is that the quality and delivery of A1 in the 
SMART and enrichment samples may be different. In the enrichment sample, A1 is 
delivered in a naturalistic fashion, which may be subject to less monitoring as in a SMART. 
However, the purpose of conducting SMART/SMARTer is to inform clinical decision-
making in practical settings. It may not be very useful to test a highly-standardized treatment 
that is not likely to be correctly implemented in practice. In SMARTs designed as pragmatic 
trials (March et al., 2010), both academic centers and community centers were recruited, 
which may represent a wide range of quality of treatment and assessment fidelity. For 
SMARTer, the interpretation of the effects of DTRs involving A1 is necessarily a pragmatic 
one and potential differences of treatment delivery in each specific application needs to be 
discussed.
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When the initial intervention is a novel treatment not immediately available in communities, 
it may be challenging to recruit patients who have naturally received this treatment. 
However, enrichment sample can still be recruited to improve efficiency of the estimation of 
DTRs containing a conventional first-stage treatment. In addition, for SMARTs such as 
CATIE (Stroup et al., 2003) and STAR*D (Rush et al., 2004), most first-line 
pharmacotherapies for treating depression and schizopherenia are commonly prescribed in 
practice. SMARTer design is useful in these settings where the first-line treatments are 
readily available but considerable uncertainty is encountered for second-line treatments 
when individuals do not achieve adequate response after a first-line treatment.
7. Supplementary Materials
Web Appendices contain the derivation of the asymptotic variance for μ̂(d1, d2) in Section 
2.2, the derivation of simplified comparative efficiency in (2) from Section 3, sensitivity 
analysis for assumption C.2 and C.3 mentioned in Section 6, simulation results for learning 
the optimal DTR from SMARTer in Section 6, and description for the code and software 
provided with the paper. Web Appendices, Tables, Figures referenced in Sections 1,2,3,4,5,6 
and the code are available with this paper at the Biometrics website on Wiley Online 
Library.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Diagram for the autism example.
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Diagram of SMARTer design.
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Contour Plot of Comparative Efficiency of SMARTer and SMART. α is the completion rate, 
β is the sample size ratio between enrichment group and original SMART group.
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